BOSTON, Feb. 02, 2016 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9th, 2016 at 1:00 p.m. ET. The conference is being held at the Waldorf Astoria Hotel in New York City.
To access a live audio webcast of the presentation, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for 90 days.
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer. The Company's synthetic immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to turn on and off, and more precisely modulate gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.
CONTACT: Contact: Lori Ann Occhiogrosso ZIOPHARM Oncology, Inc. 617-259-1987 email@example.com David Pitts Argot Partners 212-600-1902 firstname.lastname@example.org